Press release


VALERIO THERAPEUTICS
 


Onxeo Announces its Financial Agenda for 2021
 

The press release in PDF


Paris (France), January 7, 2021 – 6.00 pm CET - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced its financial agenda for 2021.


* This preliminary agenda may be modified. Press releases are published after financial markets close.
 

About Onxeo

Valerio Therapeutics (Euronext Growth Paris) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners..

PlatON is Valerio Therapeutics’s proprietary chemistry platform of DNA decoy therapeutics, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its DNA decoy therapeutic mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe and the US in combination with other treatment modalities in difficult-to-treat solid tumors.

VIO-01 (formerly OX425), the second compound from platON, is a novel pan-DDR Decoy with high antitumor activity. It also mediates multiple immunostimulatory effects by activating the STING pathway. OX425 is currently undergoing IND-enabling preclinical development.

For further information, please visit https://valeriotx.com/

https://valeriotx.com/fr/

Valerio Therapeutics
Investor relations
Phone nb.: +33 1 45 58 76 00
Email: investors@valeriotx.com
NewCap
Dušan Orešanský / Nicolas Fossiez
Investor Relations / Strategic Communications
Phone nb.: +33 1 44 71 94 92
Email: valeriotx@newcap.eu
NewCap
Arthur Rouillé
Media Relations
Phone nb.: +33 1 44 71 00 15
Email: arouille@newcap.eu
 
 
 
 
-